Advertisement

Topics

The Brazilian market for monoclonal antibodies used in cancer treatment.

07:00 EST 29th November 2018 | BioPortfolio

Summary of "The Brazilian market for monoclonal antibodies used in cancer treatment."

Monoclonal antibodies (mABs) have been indicated as an innovative technology for the treatment of some types of cancer, since they are capable of targeting and selectively killing tumor cells. However, the high costs of these therapies raise questions as to the sustainability of access. This study aimed to identify the principal characteristics of monoclonal antibodies used in cancer treatment with active marketing authorization in Brazil as of 2016. This was a descriptive retrospective analysis based on consultation of the Brazilian Health Regulatory Agency (Anvisa) website, in which these mABs were characterized according to the target antigen, type of antibody, year of registration, therapeutic indications, and applicant. A total of 14 antibodies were identified with action on seven different target antigens. The most frequent clinical indications were for lymphomas, leukemias, breast cancer, and colorectal cancer. As for type, the study identified three chimeric, six humanized, and five human antibodies. Roche was the applicant in 6 of the 14 mABs, or 43% of the marketing authorization. It was possible to discuss the idea of me-too medicines in the biological market and the idea of a differentiated oligopoly, as well as to think about the tensions in this kind of market. It is expected that the development of new products, although to act on the same biological target, represent the possibility of a competitive increase and, as a result, a decrease in prices practiced by companies. However, this becomes a problem when it is the same pharmaceutical industry that launches on the market new antibodies directed to the same target, with no relevant changes.

Affiliation

Journal Details

This article was published in the following journal.

Name: Cadernos de saude publica
ISSN: 1678-4464
Pages: e00010918

Links

DeepDyve research library

PubMed Articles [31255 Associated PubMed Articles listed on BioPortfolio]

Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases.

Since Nobel laureate Paul Ehrlich proposed the concept of magic bullet in 1906, Köhler and Milstein discovered Hybridoma technology in 1975, and Greg Winter pioneered the technique to humanize monocl...

Generation of Rat Monoclonal Antibodies Against a Deubiquitinase, Ovarian Tumor Domain-Containing Protein 1.

Ovarian tumor domain-containing protein 1 (OTUD1), an OTU-family deubiquitinating enzyme, has been reported to be involved in cancer progression through the regulation of p53 and SMAD7. However, the p...

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.

Upregulated expression and aberrant activation of the epidermal growth-factor receptor (EGFR) are found in lung cancer, making EGFR a relevant target for non-small-cell lung cancer (NSCLC). Treatment ...

Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity.

Monoclonal antibodies are established treatment options in cancer therapy. However, not all patients benefit from antibody therapy. Basic research and findings from clinical trials revealed that certa...

Generation and characterization of monoclonal antibodies that recognize human and murine supervillin protein isoforms.

Supervillin isoforms have been implicated in cell proliferation, actin filament-based motile processes, vesicle trafficking, and signal transduction. However, an understanding of the roles of these pr...

Clinical Trials [13455 Associated Clinical Trials listed on BioPortfolio]

Monoclonal Antibodies Elimination in Breast Cancer Patient

This Study evaluates covariables being able to potentially influence the elimination of the monoclonal antibodies (trastuzumab, bevacizumab and denosumab).

Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the ...

Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma That Has Relapsed After High-Dose Chemotherapy and Autologous Stem Cell Transplantation

RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and deliver cancer-killing substances to them without harming normal cells. Radiolabeled monoclonal antibodies ca...

Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the...

Prospective Evaluation of Breast Cancer at Brazilian Institutions - Project AMAZONA III

The principal goal of this study is to describe the epidemiology of breast cancer in the Brazilian population

Medical and Biotech [MESH] Definitions

Loss of detectable antigen from the surface of a cell after incubation with antibodies. This is one method in which some tumors escape detection by the immune system. Antigenic modulation of target antigens also reduces the therapeutic effectiveness of treatment by monoclonal antibodies.

Antibodies obtained from a single clone of cells grown in mice or rats.

Antibodies produced by clones of cells such as those isolated after hybridization of activated B LYMPHOCYTES with neoplastic cells. These hybrids are often referred to as HYBRIDOMAS.

Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.

Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Relevant Topics

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...


Searches Linking to this Article